Based on the request for the "full text" of , this specific file name does not appear in official scientific databases or public documentation.
: For patients with GvHD-related complications, treatments such as Eculizumab are being used to inhibit the C5 complement pathway, though this requires careful monitoring for infections like Neisseria meningitidis . Technical Context (Digital Files) gvh-496.mp4
: Recent studies focus on identifying risk factors like HSCT-TMA (Thrombotic Microangiopathy), which can exacerbate GvHD symptoms. Modern treatment strategies emphasize early detection through organ biopsies and staining for markers like C4d and C5b-9 [5, 8]. Based on the request for the "full text"
: Advanced research is exploring VHH-CAR T cells (nanobody-based chimeric antigen receptor T cells). These are designed to target specific antigens like MET in solid tumors while minimizing the "tonic signaling" that often leads to T-cell exhaustion. which can exacerbate GvHD symptoms.